Attovia Therapeutics (ATTO) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Attovia Therapeutics is the larger company by market cap ($744.6 million vs $677.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATTO | OABI |
|---|---|---|
| Share price | $16.31 | $4.66 |
| Market cap | $744.57M | $677.52M |
| 1-day change | -0.67% | +2.19% |
| YTD return | — | +151.89% |
| 1-year return | — | +166.29% |
| 5-year return | — | -53.26% |
| EPS (TTM) | $-2.74 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $28.00 | $5.43 |
| 52-week low | $15.48 | $1.30 |
| Distance from 52-week high | -41.75% | -14.18% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +158.74% | +78.76% |
| Average volume | 457.37K | 1.47M |
| Shares outstanding | 45.65M | 145.39M |
| Employees | 44 | 89 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Attovia Therapeutics
ATTO stock →Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Healthcare · Biotechnology · 44 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Healthcare · Biotechnology · 89 employees
ATTO vs OABI FAQ
Which is bigger, Attovia Therapeutics or OmniAb?
Attovia Therapeutics (ATTO) is larger, with a market capitalization of $744.57M compared with $677.52M for OmniAb (OABI).
Are Attovia Therapeutics and OmniAb in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.